No Data
Haite Biotech: 2024 Annual Report
Haite Biotech: Report for the first quarter of 2025
Haite Biotech: 2024 Annual Report Summary
Wuhan Hiteck Biological Pharma (300683.SZ) released its performance for the year 2024, reporting a net loss attributable to shareholders of 69.3487 million yuan.
Wuhan Hiteck Biological Pharma (300683.SZ) released its annual report for 2024, during the reporting period, the company achieved revenue of 6...
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Wuhan Hiteck Biological Pharma (300683.SZ): plans to reduce the subscribed capital contribution amount of the Fund.
On March 18, Gelonghui reported that Wuhan Hiteck Biological Pharma (300683.SZ) announced that based on adjustments to the Global Strategy, it was agreed among all partners to change the subscribed capital contribution of the Q ingning Fund from RMB 240 million to RMB 120 million. The company's subscribed capital contribution decreased from RMB 10 million to RMB 5 million, reducing the subscribed capital contribution by RMB 5 million. This reduction in the subscribed capital contribution of the Q ingning Fund will not affect the normal operation of the fund, is beneficial for the company to integrate internal resources, improve the efficiency of MMF utilization, meet operational needs, and align with the strategic development requirements of the company.
